Bailard’s Climb Bio CLYM Stock Holding History

Bailard’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$125K	Hold	10,900	–	–	﹤0.01%	736
2026 Q2	$142K	Buy	+10,900	New	+$113K	﹤0.01%	750
2025 Q1	–	Sell	-56,800	Closed	-$102K	–	855
2024 Q4	$102K	Buy	+56,800	New	+$206K	﹤0.01%	715

Other funds holding CLYM

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Bailard's CLYM Position: Q3 2026 in Review

Bailard held its Climb Bio (CLYM) position steady in Q3 2026 at 10,900 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #736.

Bailard first reported a position in CLYM in Q4 2024 and has held it in 3 quarters since. The position peaked at $142K in Q2 2026. 3 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

Bailard held 10,900 shares of Climb Bio worth $125K as of Q3 2026.
Bailard left its Climb Bio share count unchanged in Q3 2026.
Climb Bio made up ﹤0.01% of Bailard's portfolio in Q3 2026, its #736 holding.
Bailard first reported a position in Climb Bio in Q4 2024 and has held it in 3 quarters since.
Bailard's Climb Bio position peaked at $142K in Q2 2026.
3 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.